AU3042601A - Therapeutic morpholino-substituted compounds - Google Patents
Therapeutic morpholino-substituted compoundsInfo
- Publication number
- AU3042601A AU3042601A AU3042601A AU3042601A AU3042601A AU 3042601 A AU3042601 A AU 3042601A AU 3042601 A AU3042601 A AU 3042601A AU 3042601 A AU3042601 A AU 3042601A AU 3042601 A AU3042601 A AU 3042601A
- Authority
- AU
- Australia
- Prior art keywords
- kinase
- diseases
- compounds
- morpholino
- conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 3
- 150000003906 phosphoinositides Chemical class 0.000 abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010011086 Coronary artery occlusion Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- -1 Morpholino-substituted pyridopyrimidine Chemical class 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17735100P | 2000-01-24 | 2000-01-24 | |
| US22582600P | 2000-08-17 | 2000-08-17 | |
| PCT/IB2001/000079 WO2001053266A1 (en) | 2000-01-24 | 2001-01-24 | Therapeutic morpholino-substituted compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3042601A true AU3042601A (en) | 2001-07-31 |
Family
ID=26873182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU3042601A Pending AU3042601A (en) | 2000-01-24 | 2001-01-24 | Therapeutic morpholino-substituted compounds |
| AU2001230426A Ceased AU2001230426C1 (en) | 2000-01-24 | 2001-01-24 | Therapeutic morpholino-substituted compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001230426A Ceased AU2001230426C1 (en) | 2000-01-24 | 2001-01-24 | Therapeutic morpholino-substituted compounds |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US6977255B2 (enExample) |
| EP (2) | EP1857443B1 (enExample) |
| JP (1) | JP4820518B2 (enExample) |
| CN (3) | CN1891693A (enExample) |
| AT (2) | ATE363471T1 (enExample) |
| AU (2) | AU3042601A (enExample) |
| CA (1) | CA2398163C (enExample) |
| CY (1) | CY1108023T1 (enExample) |
| DE (1) | DE60128655T2 (enExample) |
| DK (1) | DK1257537T3 (enExample) |
| ES (1) | ES2286093T3 (enExample) |
| NZ (1) | NZ520300A (enExample) |
| PT (1) | PT1257537E (enExample) |
| WO (1) | WO2001053266A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3029041T1 (sl) | 2000-04-25 | 2020-08-31 | Icos Corporation | Inhibitorji humane delta fosfatidil-inozitol 3-kinaze |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| GB0119863D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| GB2405870B (en) * | 2001-08-14 | 2005-07-06 | Cancer Rec Tech Ltd | DNA-PK inhibitors |
| US20040235866A1 (en) * | 2001-09-05 | 2004-11-25 | Takahisa Hanada | Lymphocytic activation inhibitor and remedial agent for autoimmune disease |
| US7049313B2 (en) | 2002-02-25 | 2006-05-23 | Kudos Pharmaceuticals Ltd. | ATM inhibitors |
| MY156407A (en) | 2002-02-28 | 2016-02-26 | Novartis Ag | 5-phenylthiazole derivatives and use as p13 kinase inhibitors |
| EP2311818B1 (en) * | 2002-02-28 | 2013-01-16 | Novartis AG | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
| JP4646626B2 (ja) * | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド３−キナーゼβの阻害 |
| CN101260104A (zh) * | 2002-08-16 | 2008-09-10 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
| JP4494205B2 (ja) | 2002-08-26 | 2010-06-30 | 武田薬品工業株式会社 | カルシウム受容体調節化合物およびその用途 |
| BR0316386A (pt) * | 2002-12-06 | 2005-09-27 | Warner Lambert Co | Benzoxazin-3-onas e seus derivados como inibidores de p13k |
| GB0305152D0 (en) * | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
| CA2522595A1 (en) * | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| JP2006523237A (ja) * | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ， インコーポレイテッド | Ｐｉ−３キナーゼインヒビタープロドラッグ |
| WO2004108709A1 (en) * | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Tetrazol benzofurancarboxamides with p13k aktivity as therapeutic agents |
| US20040259926A1 (en) * | 2003-06-05 | 2004-12-23 | Bruendl Michelle M. | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents |
| CA2527341A1 (en) * | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents |
| ATE461193T1 (de) | 2003-08-13 | 2010-04-15 | Kudos Pharm Ltd | Aminopyrone und ihre verwendung als atm inhibitoren |
| WO2005023800A1 (en) * | 2003-09-04 | 2005-03-17 | Warner-Lambert Company Llc | Halo substituted benzo`b! thiophenes with pi3k inhibitory activity as therapeutic agents |
| DE602004007284T2 (de) * | 2003-10-31 | 2008-02-28 | Warner-Lambert Company Llc | PYRIMIDINE ALS INHIBITOREN VON PHOSPHOINOSITID-3-KINASEN (PI3Ks) |
| AU2005228845A1 (en) * | 2004-01-26 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| CN1300163C (zh) * | 2004-06-23 | 2007-02-14 | 南京大学 | 3－羟基色原酮糖苷及其制法和用途 |
| US7402607B2 (en) | 2004-09-20 | 2008-07-22 | Kudos Pharmaceuticals Limited | DNA-PK inhibitors |
| TW200638938A (en) | 2005-02-09 | 2006-11-16 | Kudos Pharm Ltd | ATM inhibitors |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| US7691858B2 (en) | 2006-04-25 | 2010-04-06 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
| DK2044026T3 (da) * | 2006-06-22 | 2014-06-30 | Prana Biotechnology Ltd | Fremgangsmde til behandling af cerebral glioma tumor |
| EP2124948B1 (en) * | 2007-02-21 | 2017-07-26 | NC bit, Inc. | Compositions for treating hyperproliferative vascular disorders and cancers |
| JP5672699B2 (ja) | 2007-04-11 | 2015-02-18 | 味の素株式会社 | 血糖降下作用化合物のスクリーニング法 |
| WO2008150827A1 (en) * | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| US20100130597A1 (en) * | 2007-07-06 | 2010-05-27 | The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service | Dna-pkcs modulates energy regulation and brain function |
| KR20100118977A (ko) * | 2008-01-25 | 2010-11-08 | 아스트라제네카 아베 | 거울상이성질체적으로 순수한 (-) 2-[1-(7-메틸-2-(모르폴린-4-일)-4-옥소-4Ｈ-피리도[1,2-α]피리미딘-9-일)에틸아미노]벤조산, 의학 치료에서의 이의 용도 및 이를 포함하는 약학 조성물-026 |
| WO2009129372A1 (en) * | 2008-04-18 | 2009-10-22 | Shenogen Pharma Group Ltd. | Compounds and methods for treating estrogen receptor-related diseases |
| MX2011003373A (es) | 2008-09-29 | 2011-06-09 | Sirtris Pharmaceuticals Inc | Quinazolinona, quinolona y analogos relacionados como moduladores de sirtuina. |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| EP2355828B1 (en) | 2008-11-13 | 2018-05-30 | Gilead Calistoga LLC | Therapies for hematologic malignancies |
| WO2011001115A1 (fr) | 2009-07-02 | 2011-01-06 | Sanofi-Aventis | Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb ) |
| ES2487623T3 (es) | 2009-07-02 | 2014-08-22 | Sanofi | Derivados de 6,7,8,9-tetrahidro-pirimido{1,2-a}pirimidin-4-ona, su preparación y su aplicación farmacéutica |
| HUE034503T2 (en) | 2009-07-02 | 2018-02-28 | Sanofi Sa | 2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine |
| CA2767064C (fr) | 2009-07-02 | 2017-11-07 | Sanofi | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| US8691829B2 (en) | 2009-07-21 | 2014-04-08 | Gilead Calistoga Llc | Treatment of liver disorders with PI3K inhibitors |
| US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| IT1403156B1 (it) * | 2010-12-01 | 2013-10-04 | Università Degli Studi Di Torino | Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi. |
| FR2969613B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique |
| PL2655375T3 (pl) | 2010-12-23 | 2015-05-29 | Sanofi Sa | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie |
| FR2969612B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique |
| ES2612492T3 (es) | 2010-12-28 | 2017-05-17 | Sanofi | Nuevos derivados de piridiminas, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT (PKB) |
| TW201335151A (zh) * | 2012-01-26 | 2013-09-01 | Daiichi Sankyo Co Ltd | 具有骨形成促進作用之色酮衍生物 |
| BR112014019750B1 (pt) | 2012-02-10 | 2020-03-03 | F. Hoffmann-La Roche Ag. | Composto, composição farmacêutica e seus usos |
| MX352962B (es) | 2012-03-01 | 2017-12-15 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal. |
| EA201691327A1 (ru) | 2012-03-05 | 2017-03-31 | Джилид Калистога Ллс | Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она |
| US9914722B2 (en) | 2012-03-23 | 2018-03-13 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| ITMI20120514A1 (it) * | 2012-03-29 | 2013-09-30 | Cnr Consiglio Naz Delle Ric Erche | Agente terapeutico per il trattamento dei vasi sanguigni |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| KR20160095161A (ko) | 2013-12-20 | 2016-08-10 | 길리아드 칼리스토가 엘엘씨 | 포스파티딜이노시톨 3-키나제 억제제의 가공 방법 |
| JP2017500319A (ja) | 2013-12-20 | 2017-01-05 | ギリアード カリストガ エルエルシー | （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態 |
| AU2015274696B2 (en) | 2014-06-13 | 2018-09-27 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| EP3298017B1 (en) * | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| MX391850B (es) | 2015-12-10 | 2025-03-19 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington |
| EP3741432B1 (en) | 2015-12-17 | 2023-05-10 | AlonBio Ltd. | Quinolin-2,4-one derivatives for inhibiting chemokine activity |
| US10646465B2 (en) | 2015-12-17 | 2020-05-12 | Biokine Therapeutics Ltd. | Small molecules against cancer |
| AU2017310526B2 (en) * | 2016-08-12 | 2021-08-12 | Edwin J. Iwanowicz | Protein kinase regulators |
| CA3043755A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
| JP2020506904A (ja) | 2017-01-27 | 2020-03-05 | シグナルアールエックス ファーマシューティカルズ，インコーポレイテッド | キナーゼ、ブロモドメイン及びチェックポイント阻害剤としてのチエノピラノン及びフラノピラノン |
| SG11201911615WA (en) | 2017-06-05 | 2020-01-30 | Ptc Therapeutics Inc | Compounds for treating huntington's disease |
| BR112019026508A2 (pt) | 2017-06-14 | 2020-07-14 | Ptc Therapeutics, Inc. | métodos para modificar o splicing do rna |
| WO2019005980A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| MX2020014098A (es) | 2018-06-27 | 2021-05-27 | Ptc Therapeutics Inc | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington. |
| CN109748914B (zh) * | 2018-12-29 | 2021-05-25 | 上海珂臻医药科技有限公司 | 吡啶并嘧啶类化合物及其应用 |
| CN114096524B (zh) | 2019-05-15 | 2025-03-04 | 阿龙拜欧有限公司 | 用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子 |
| AR121719A1 (es) | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| CN111533721B (zh) * | 2020-05-15 | 2022-04-26 | 浙江大学 | 苯并吡喃酮或喹啉酮类化合物及其应用 |
| WO2021247859A1 (en) * | 2020-06-03 | 2021-12-09 | Yumanity Therapeutics, Inc. | Pyridopyrimidines and methods of their use |
| WO2022164812A1 (en) * | 2021-02-01 | 2022-08-04 | Geode Therapeutics Inc. | Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof |
| BR112023022940A2 (pt) | 2021-05-03 | 2024-01-23 | Petra Pharma Corp | Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças |
| JP7702057B2 (ja) | 2021-05-27 | 2025-07-03 | ペトラ・ファーマ・コーポレイション | がんの治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤 |
| TW202329930A (zh) | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| CA3232906A1 (en) * | 2021-10-07 | 2023-04-13 | Alessandro Boezio | Pi3k-alpha inhibitors and methods of use thereof |
| WO2025136936A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Agonists of trem2 activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS604170A (ja) * | 1983-06-21 | 1985-01-10 | Nippon Shinyaku Co Ltd | キノロン誘導体 |
| RU2118321C1 (ru) * | 1988-12-21 | 1998-08-27 | Дзе Апджон Компани | Замещенные бензопираноны и их фармацевтически приемлемые соли и гидраты |
| US5703075A (en) * | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| CA2081577A1 (en) * | 1990-06-20 | 1991-12-21 | Ronald B. Gammill | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones |
-
2001
- 2001-01-24 CN CNA200610084723XA patent/CN1891693A/zh active Pending
- 2001-01-24 US US10/181,485 patent/US6977255B2/en not_active Expired - Fee Related
- 2001-01-24 ES ES01902568T patent/ES2286093T3/es not_active Expired - Lifetime
- 2001-01-24 AT AT01902568T patent/ATE363471T1/de active
- 2001-01-24 AU AU3042601A patent/AU3042601A/xx active Pending
- 2001-01-24 AU AU2001230426A patent/AU2001230426C1/en not_active Ceased
- 2001-01-24 WO PCT/IB2001/000079 patent/WO2001053266A1/en not_active Ceased
- 2001-01-24 AT AT07009194T patent/ATE551325T1/de active
- 2001-01-24 CN CNA2006100847155A patent/CN1891699A/zh active Pending
- 2001-01-24 CN CNB018067522A patent/CN1263743C/zh not_active Expired - Fee Related
- 2001-01-24 EP EP07009194A patent/EP1857443B1/en not_active Expired - Lifetime
- 2001-01-24 JP JP2001553268A patent/JP4820518B2/ja not_active Expired - Fee Related
- 2001-01-24 NZ NZ520300A patent/NZ520300A/en not_active IP Right Cessation
- 2001-01-24 CA CA2398163A patent/CA2398163C/en not_active Expired - Fee Related
- 2001-01-24 PT PT01902568T patent/PT1257537E/pt unknown
- 2001-01-24 DE DE60128655T patent/DE60128655T2/de not_active Expired - Lifetime
- 2001-01-24 DK DK01902568T patent/DK1257537T3/da active
- 2001-01-24 EP EP01902568A patent/EP1257537B1/en not_active Expired - Lifetime
-
2004
- 2004-10-12 US US10/961,062 patent/US7405211B2/en not_active Expired - Fee Related
-
2007
- 2007-07-20 CY CY20071100971T patent/CY1108023T1/el unknown
-
2008
- 2008-01-24 US US12/019,061 patent/US7572791B2/en not_active Expired - Fee Related
- 2008-05-06 US US12/115,563 patent/US20080312233A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3042601A (en) | Therapeutic morpholino-substituted compounds | |
| WO2005082863A3 (en) | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors | |
| NO20042378L (no) | A2B-adenosinreseptorantagonister | |
| JP5351770B2 (ja) | ビオチンまたはビオチン誘導体との少なくとも１つの共有結合を含む低分子量ヘパリン、これらの作製方法およびそれらの使用。 | |
| ATE255093T1 (de) | Benzamidverbindung und ihre medizinische verwendung | |
| JP2011510071A (ja) | 鏡像異性的に純粋な（−）２−［１−（７−メチル−２−（モルホリン−４−イル）−４−オキソ−４Ｈ−ピリド［１，２−ａ］ピリミジン−９−イル）エチルアミノ］安息香酸、医学的療法における該物質の使用、および該物質を含む薬学的組成物−０２６ | |
| CA2417897A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| PT1000033E (pt) | Derivados heterociclicos que inibem o factor xa | |
| AU2001295482A1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof | |
| RU2148056C1 (ru) | Замещенные азетидиноны, способ их получения, фармацевтическая композиция и способ лечения | |
| EA013078B1 (ru) | Применение диосметиновых соединений при лечении и профилактике тромботических патологий | |
| NO20064295L (no) | Bruk av metylenamidderivater i kardiovaskulaere lidelser | |
| BR9914893A (pt) | Cromenona e derivados de cromanona como inibidores de integrina | |
| CN1387508A (zh) | N－胍基烷基酰胺、其制备、其应用、和含有它们的药物制剂 | |
| CN1393446B (zh) | 稠合吡唑化合物 | |
| AU6670196A (en) | Thienopyrimidine derivatives, their production and use | |
| JPH05500805A (ja) | 抗血栓症作用を有する組合せ調剤 | |
| CA2534171A1 (en) | Bicyclic indoline sulfonamide derivatives | |
| SE9900834D0 (sv) | Novel combination | |
| KR101178793B1 (ko) | 스텐트 표면의 헤파린 코팅 방법 | |
| TR200103853T2 (tr) | Spiro bağlı trisiklik bileşikler. | |
| Radziwon et al. | Tissue factor pathway inhibitor (TFPI) in patients with occlusive arterial diseases in consideration with risk factors and conservative treatment of the disease | |
| CN113116885A (zh) | 一种茶多酚类化合物在制备抗血栓药物中的应用 | |
| DE602004009097D1 (de) | 1.3.4-triaza-phenalen- und 1,3,4,6-tetraazaphenalen-derivative | |
| Isobe et al. | Antithrombin prevents stress-induced gastric mucosal injury by increasing the gastric prostacyclin level in rats |